» Articles » PMID: 38931858

Applicability of MDR1 Overexpressing Abcb1KO-MDCKII Cell Lines for Investigating In Vitro Species Differences and Brain Penetration Prediction

Overview
Journal Pharmaceutics
Publisher MDPI
Date 2024 Jun 27
PMID 38931858
Authors
Affiliations
Soon will be listed here.
Abstract

Implementing the 3R initiative to reduce animal experiments in brain penetration prediction for CNS-targeting drugs requires more predictive in vitro and in silico models. However, animal studies are still indispensable to obtaining brain concentration and determining the prediction performance of in vitro models. To reveal species differences and provide reliable data for IVIVE, in vitro models are required. Systems overexpressing MDR1 and BCRP are widely used to predict BBB penetration, highlighting the impact of the in vitro system on predictive performance. In this study, endogenous Abcb1 knock-out MDCKII cells overexpressing MDR1 of human, mouse, rat or cynomolgus monkey origin were used. Good correlations between ERs of 83 drugs determined in each cell line suggest limited species specificities. All cell lines differentiated CNS-penetrating compounds based on ERs with high efficiency and sensitivity. The correlation between in vivo and predicted K was the highest using total ER of human MDR1 and BCRP and optimized scaling factors. MDR1 interactors were tested on all MDR1 orthologs using digoxin and quinidine as substrates. We found several examples of inhibition dependent on either substrate or transporter abundance. In summary, this assay system has the potential for early-stage brain penetration screening. IC comparison between orthologs is complex; correlation with transporter abundance data is not necessarily proportional and requires the understanding of modes of transporter inhibition.

Citing Articles

Modulation of Multispecific Transporters by Extract and Its Major Phytoconstituents.

Szilvasy N, Lajer P, Horvath A, Veres K, Hohmann J, Schelz Z Pharmaceutics. 2024; 16(11).

PMID: 39598486 PMC: 11597817. DOI: 10.3390/pharmaceutics16111363.

References
1.
Chu X, Bleasby K, Evers R . Species differences in drug transporters and implications for translating preclinical findings to humans. Expert Opin Drug Metab Toxicol. 2012; 9(3):237-52. DOI: 10.1517/17425255.2013.741589. View

2.
Aller S, Yu J, Ward A, Weng Y, Chittaboina S, Zhuo R . Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding. Science. 2009; 323(5922):1718-22. PMC: 2720052. DOI: 10.1126/science.1168750. View

3.
Kamiie J, Ohtsuki S, Iwase R, Ohmine K, Katsukura Y, Yanai K . Quantitative atlas of membrane transporter proteins: development and application of a highly sensitive simultaneous LC/MS/MS method combined with novel in-silico peptide selection criteria. Pharm Res. 2008; 25(6):1469-83. DOI: 10.1007/s11095-008-9532-4. View

4.
Shao Y, Ayesh S, Stein W . Mutually co-operative interactions between modulators of P-glycoprotein. Biochim Biophys Acta. 1997; 1360(1):30-8. DOI: 10.1016/s0925-4439(96)00065-8. View

5.
Baltes S, Gastens A, Fedrowitz M, Potschka H, Kaever V, Loscher W . Differences in the transport of the antiepileptic drugs phenytoin, levetiracetam and carbamazepine by human and mouse P-glycoprotein. Neuropharmacology. 2006; 52(2):333-46. DOI: 10.1016/j.neuropharm.2006.07.038. View